Urinary thromboxane and risk of cardiovascular events: role of aspirin

European Heart Journal

6 March 2024

Organised by:

Read full article

Contributors

John W Eikelboom

John W Eikelboom

Author

McMaster University Hamilton , Canada

Paul C Kruger

Paul C Kruger

Author

You may be interested in

Webinar

Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

6 July 2023

Congress Presentation

Thrombin generation and platelet function in patients on RAAS inhibitors

2 September 2019

Congress Presentation

Role of urinary 11-dehydro-thromboxane B2 as a predictor of preeclampsia in pregnant high-risk women on low-dose aspirin treatment

31 August 2025

Congress Presentation

Residual platelet activity and systemic inflammation in patients with chronic coronary syndrome in the context of aspirin monotherapy.

29 June 2021

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources